Press Release - Oslo, Norway, May 12, 2024: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:
688176) communicated today that the National Medical Products Administration
(NMPA) has accepted its new drug application (NDA) for the regulatory review of
Cevira[®] (APL-1702, Hexaminolevulinate Hydrochloride Ointment Photodynamic
Therapy System) for potential marketing authorization in China. Cevira (APL
-1702) is a photodynamic drug-device combination product in development for the
non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL),
licensed to Asieris by Photocure.
"We are pleased that Cevira continues to advance toward market approval in
China, as it can serve an important non-invasive option to treat pre-cervical
cancer without the complications of surgical intervention," said Dan Schneider,"
President and CEO of Photocure. "Asieris continues to be a valued partner to
Photocure, with solid execution on both programs that it has licensed from us.
We look forward to further announcements on the regulatory progress of Cevira as
well as Asieris' pending NDA for Hexvix in China."
The Asieris media release states: "APL-1702 is a first-in-class, non-surgical
treatment for cervical HSIL with its efficacy proven in an international phase
III trial. It heralds a potential paradigm shift in the treatment of
precancerous cervical lesions, with the clinical focus moving from excision to
long-term disease management. Emphasis lies in optimizing the delicate balance
between treatment risks and benefits, striving to minimize or delay invasive
procedures while effectively reversing the progression of the disease."
Read Asieris' full media release here: https://asieris.com/asieris-announces
-nmpa-acceptance-of-nda-for-apl-1702-a-non-surgical-therapy-for-treating
-cervical-hsil/
Note to editors:
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.
About Cevira[®]
Cevira[®] (APL-1702) is a photodynamic drug-device combination product in
development. Based on the principles of photodynamic therapy, the Cevira product
aims to use a photosensitizer in combination with light activation to produce a
therapeutic effect as a non-surgical treatment of high-grade squamous
intraepithelial lesions (HSIL) in patients aged 18 years and above, excluding
carcinoma in situ.
Photocure developed Cevira through Phase I and Phase II trials, and the global
rights for development and commercialization were out-licensed to Asieris
Meditech Co., Ltd in 2019. In November 2020 Asieris initiated the phase III
clinical trial for APL-1702 (Cevira) which achieved its primary endpoint in
September 2023, Clinical trial number:
NCT04484415 (https://classic.clinicaltrials.gov/ct2/show/NCT04484415).
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma
company specializing in discovering, developing and commercializing innovative
drugs for the treatment of genitourinary tumors and other related diseases.
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
